** Shares of Unity Biotechnology UBX.O fall 35.3% to $1.18
** Drug developer says its treatment for a type of eye disease failed to meet the main goal of a mid-stage trial
** Co was testing the treatment in patients with diabetic macular edema $(DME.AU)$, an eye condition that causes swelling in the retina in those who have poor vision despite prior treatment
** Co says the treatment, UBX1325, did not meet the main goal of statistical non-inferiority to Regeneron's REGN.O Eylea, the standard of care treatment for patients with DME
** Co, however, says UBX1325 showed improvements in clarity of vision of over 5 letters at weeks 24 and 36
** Co anticipates the complete results from the remaining patients in Q2 of 2025
** Stock had fallen 49.4% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。